SGCG and glioma: Based on these studies, we recently implemented vaccine trials evaluating safety and immunological activity of type-1 inducing DCs loaded with synthetic peptides encoding these GAA-derived CTL epitopes in HLA-A2+ patients with recurrent glioma (UPCI 04-136 and 05-115).